title: Effects of pioglitazone on subclinical atherosclerosis and insulin resistance in nondiabetic renal allograft recipients.
abstract: BACKGROUND
  The aim of this study was to evaluate the effect of pioglitazone treatment on the progression of subclinical atherosclerosis and insulin resistance in renal allograft recipients with no preoperative history of diabetes.
  
  
  METHODS
  Eighty-three patients without diabetes were randomly assigned to either the pioglitazone group or the control group. Carotid intima-media thickness (IMT), serum adiponectin level and lipid profile were assessed before transplantation and at 12 months after transplantation. Insulin secretory function and insulin resistance were evaluated by the oral glucose tolerance test.
  
  
  RESULTS
  The pioglitazone group showed a significant reduction in the mean and maximum carotid IMT compared with the control group after 12 months (mean carotid IMT, 0.05 +/- 0.04 vs -0.03 +/- 0.07 mm, P < 0.001; maximum carotid IMT, 0.08 +/- 0.05 vs -0.05 +/- 0.09 mm, P < 0.001). Pioglitazone increased the adiponectin level, and the change in adiponectin was negatively correlated with carotid IMT changes. Pioglitazone treatment increased the insulin sensitivity index compared with the control group (-0.8 +/- 3.1x10(-)(2) vs +1.1 +/- 3.7x10(-)(2), P = 0.036).
  
  
  CONCLUSIONS
  These results suggest that pioglitazone treatment reduces the progression of carotid IMT and improves insulin resistance in renal allograft recipients without a history of diabetes. Trial Registration. Clinicaltrials.gov Identifier: NCT00598013.
authors.affiliation: Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon 443-721, Korea.
authors.forename: Seung Jin
authors.initials: SJ
authors.lastname: Han
authors.forename: Kyu Yeon
authors.initials: KY
authors.lastname: Hur
authors.forename: Yu Seun
authors.initials: YS
authors.lastname: Kim
authors.forename: Eun Seok
authors.initials: ES
authors.lastname: Kang
authors.forename: Soon Il
authors.initials: SI
authors.lastname: Kim
authors.forename: Myoung Soo
authors.initials: MS
authors.lastname: Kim
authors.forename: Jung Young
authors.initials: JY
authors.lastname: Kwak
authors.forename: Dae Jung
authors.initials: DJ
authors.lastname: Kim
authors.forename: Sung Hee
authors.initials: SH
authors.lastname: Choi
authors.forename: Bong Soo
authors.initials: BS
authors.lastname: Cha
authors.forename: Hyun Chul
authors.initials: HC
authors.lastname: Lee
mesh_terms: D052242:Adiponectin / Q000097:blood; D000328:Adult; D050197:Atherosclerosis / Q000188:drug therapy* / Q000503:physiopathology; D002339:Carotid Arteries / Q000000981:diagnostic imaging; D018450:Disease Progression; D005260:Female; D018149:Glucose Intolerance / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D007333:Insulin Resistance / Q000502:physiology*; D016030:Kidney Transplantation / Q000502:physiology*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D000077205:Pioglitazone; D045162:Thiazolidinediones / Q000494:pharmacology / Q000627:therapeutic use*; D014184:Transplantation, Homologous; D014463:Ultrasonography
chemical_list: D052242:Adiponectin; D007004:Hypoglycemic Agents; D008055:Lipids; D045162:Thiazolidinediones; D000077205:Pioglitazone